AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AROA BIOSURGERY LTD

0.400

+0.0102.56%

Volume:107.43K

Turnover:43.03K

Market Cap:137.96M

PE:-19.34

High:0.407

Open:0.400

Low:0.390

Close:0.390

Loading ...

Overview Company News Filings

Aroa Biosurgery Limited's (ASX:ARX) Profit Outlook

Simply Wall St.

BUZZ-Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge

Simply Wall St.

Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business

Simply Wall St.

ASX Penny Stocks Spotlight For February 2025

Simply Wall St.

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge

Simply Wall St.

ASX Market Close: Westpac & UBS predict February rate cut | January 29, 2025

The Market Herald

Why Accent, Aroa, Playside, and Premier Investments shares are tumbling today

BRIEF-Aroa Biosurgery Sees FY25 Total Revenue NZ$81-84 Mln

BUZZ-Australia's Aroa Biosurgery eyes worst day ever on lowering FY25 forecasts

Aroa Biosurgery Sees FY Normalised Ebitda Profit of Nz$2-4 Mln

THOMSON REUTERS

Aroa Biosurgery Ltd - Full-Year FY25 Guidance Expected to Be Nz$81-84 Mln Total Revenue

THOMSON REUTERS

New study highlights effectiveness and cost benefits of Myriad™ in lower limb salvage surgeries.

Insider Returns Down To NZ$223k As Aroa Biosurgery's Stock Dips 10.0%

Simply Wall St.

Companies Like Aroa Biosurgery (ASX:ARX) Can Afford To Invest In Growth

Simply Wall St.

Aroa Biosurgery Says Real-World Study Backs Efficacy of Regenerative Product

MT Newswires Live

Insiders own 25% of Aroa Biosurgery Limited (ASX:ARX) shares but individual investors control 51% of the company

Simply Wall St.

Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%

Simply Wall St.

The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts

Simply Wall St.

ASX Penny Stocks To Watch In November 2024

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARX.AU\",,,,,undefined,":{"symbol":"ARX.AU","market":"AU","secType":"STK","nameCN":"AROA BIOSURGERY LTD","latestPrice":0.4,"timestamp":1745388720000,"preClose":0.39,"halted":0,"volume":107434,"delay":0,"nameEN":"AROA BIOSURGERY LTD","floatShares":259472084,"shares":344900256,"eps":-0.020706035588645002,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"04-23 16:12:00 AEST","open":0.4,"high":0.407,"low":0.39,"amount":43030,"amplitude":0.04359,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.020706035588645002,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745452800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.39,"openAndCloseTimeList":[[1745366400000,1745388000000]],"volumeRatio":0.2697779580766594,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARX.AU\",,,,,undefined,":{"symbol":"ARX.AU","floatShares":259472084,"roa":"-5.67%","roe":"-8.05%","lyrEps":-0.028921,"volumeRatio":0.2697779580766594,"shares":344900256,"dividePrice":0,"high":0.407,"amplitude":0.04359,"preClose":0.39,"low":0.39,"week52Low":0.35,"pbRate":"1.60","psRate":"1.93","week52High":0.815,"institutionHeld":0,"latestPrice":0.4,"eps":-0.020685360484314803,"divideRate":0,"volume":107434,"delay":0,"ttmEps":-0.020685360484314803,"open":0.4,"prevYearClose":0.77,"prevWeekClose":0.405,"prevMonthClose":0.425,"prevQuarterClose":0.425,"fiveDayClose":0.44,"twentyDayClose":0.44,"sixtyDayClose":0.78,"earningDate":1745856000000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529434368","title":"Aroa Biosurgery Limited's (ASX:ARX) Profit Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2529434368","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529434368?lang=en_us&edition=fundamental","pubTime":"2025-04-21 12:11","pubTimestamp":1745208714,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Aroa Biosurgery Limited's  future prospects. Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix  technology in the United States and internationally. The AU$140m market-cap company posted a loss in its most recent financial year of NZ$11m and a latest trailing-twelve-month loss of NZ$7.6m shrinking the gap between loss and breakeven. Many investors are wondering about the rate at which Aroa Biosurgery will turn a profit, with the big question being “when will the company breakeven?”We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.Working backwards from analyst estimates, it turns out that they expect the company to grow 60% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aroa-biosurgery-limiteds-asx-arx-041154212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2527978495","title":"BUZZ-Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2527978495","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527978495?lang=en_us&edition=fundamental","pubTime":"2025-04-14 13:17","pubTimestamp":1744607871,"startTime":"0","endTime":"0","summary":"BUZZ-Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs** Index of Australian Healthcare stocks .AXHJ rises 1.9%, tracking broadly positive market sentiment .A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nL4N3QS0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","CSL.AU","BK7503","BK7511","NEU.AU","BK7096","PNV.AU","BK7501","NAN.AU","BK7126","TRJ.AU","BK7067","BK7508","ARX.AU"],"gpt_icon":0},{"id":"2525833510","title":"Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2525833510","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525833510?lang=en_us&edition=fundamental","pubTime":"2025-04-08 04:40","pubTimestamp":1744058410,"startTime":"0","endTime":"0","summary":"Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/why-investors-shouldnt-be-surprised-by-aroa-biosurgery-limit-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARX.AU","BK7067","ISBC","BK4211"],"gpt_icon":0},{"id":"2522032211","title":"Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2522032211","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522032211?lang=en_us&edition=fundamental","pubTime":"2025-03-25 05:38","pubTimestamp":1742852302,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-asxarx-is-in-a-strong-position-to-grow-its-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2513238863","title":"ASX Penny Stocks Spotlight For February 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2513238863","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513238863?lang=en_us&edition=fundamental","pubTime":"2025-02-21 12:11","pubTimestamp":1740111065,"startTime":"0","endTime":"0","summary":"The Australian stock market has seen a slight downturn, with the ASX200 slipping by 0.17% due to pressures from consumer discretionary stocks and banking shares, despite strength in utilities and materials sectors. In this context, investors are increasingly looking at diverse opportunities beyond traditional large-cap stocks. Penny stocks, though an older term, still represent smaller or emerging companies that can offer potential value when backed by strong financials and growth prospects. This article will spotlight three such penny stocks on the ASX that may provide both stability and potential upside for investors seeking to explore smaller companies with promising futures.ASX:ARX Debt to Equity History and Analysis as at Feb 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-penny-stocks-spotlight-february-041105310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7132","DSK.AU","BK7062","IGL.AU","MXI.AU","XKO.AU","BK7067","BK7070","BK7048","EZZ.AU","BK7077","EVO.AU","ANG.AU","ARX.AU","XJO.AU","BK7128","CAF.AU","MHJ.AU","BK7045","XAO.AU","GTN.AU","BK7095","ASM.AU","LBL.AU","HLO.AU","BK7088"],"gpt_icon":0},{"id":"2511810189","title":"Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2511810189","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511810189?lang=en_us&edition=fundamental","pubTime":"2025-02-16 06:22","pubTimestamp":1739658120,"startTime":"0","endTime":"0","summary":"Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/why-investors-shouldnt-be-surprised-by-aroa-biosurgery-limit-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4211","BK7067","ARX.AU"],"gpt_icon":0},{"id":"2507504280","title":"ASX Market Close: Westpac & UBS predict February rate cut | January 29, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507504280","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507504280?lang=en_us&edition=fundamental","pubTime":"2025-01-29 13:44","pubTimestamp":1738129440,"startTime":"0","endTime":"0","summary":"The ASX200 closed up 0.57% at 8,447 points.The critical trimmed mean inflation measure was up 3.2% on an annual basis, compared to 3.6% in the September quarter. This was below the 3.3% expected by market economists for the trimmed mean.In response, Westpac, UBS, and Bendigo and Adelaide Bank all pulled forward their expectations for the Reserve Bank’s next interest rate cut, from May to February.In contrast, money markets predict a 90% chance of a February cut and economists have fallen into line.Utilities was the best performing sector, up 2%, followed by IT, up 1.8% and Real Estate, up 1.66%. Materials was the worst performer, down 0.1%.DroneShield  closed up 4.07% on the release of its quarterlies. The company booked a 6.3% increase in revenue to $57.5 million, and a robust sales pipeline valued at $1.2 billion.Star Entertainment  closed up 13.04% after agreeing to sell the Star Sydney Event Centre and other additional spaces to Foundation Theatres for $60 million.Pilbara Minerals ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-westpac-ubs-predict-february-rate-cut-january-29-2025-2025-01-29/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["PLS.AU","BK7507","DRO.AU","SGR.AU","AX1.AU","WCN.AU","BK7135","WBC.AU","BK7067","ARX.AU","BK7078","BK7115","BK7021","BK7095","BK7504","BK7511"],"gpt_icon":0},{"id":"2507457129","title":"Why Accent, Aroa, Playside, and Premier Investments shares are tumbling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2507457129","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507457129?lang=en_us&edition=fundamental","pubTime":"2025-01-29 10:12","pubTimestamp":1738116779,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.9% to 8,475.3 points. Four ASX shares that have failed to f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/29/why-accent-aroa-playside-and-premier-investments-shares-are-tumbling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["ARX.AU","BK7021","BK7153","XJO.AU","BK7067","PMV.AU","PLY.AU","MYR.AU","BK7011","BK7029","AX1.AU"],"gpt_icon":0},{"id":"2507448576","title":"BRIEF-Aroa Biosurgery Sees FY25 Total Revenue NZ$81-84 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2507448576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507448576?lang=en_us&edition=fundamental","pubTime":"2025-01-29 09:22","pubTimestamp":1738113754,"startTime":"0","endTime":"0","summary":"BRIEF-Aroa Biosurgery Sees FY25 Total Revenue NZ$81-84 MlnJan 29 (Reuters) - Aroa Biosurgery Ltd ARX.AX:FULL-YEAR FY25 GUIDANCE EXPECTED TO BE NZ$81-84 MILLION TOTAL REVENUESEES FY NORMALISED EBITDA PROFIT OF NZ$2-4 MILLIONFurther company coverage: ARX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OO18D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU"],"gpt_icon":0},{"id":"2507495576","title":"BUZZ-Australia's Aroa Biosurgery eyes worst day ever on lowering FY25 forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2507495576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507495576?lang=en_us&edition=fundamental","pubTime":"2025-01-29 09:20","pubTimestamp":1738113612,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Aroa Biosurgery eyes worst day ever on lowering FY25 forecasts** Shares of Aroa Biosurgery ARX.AX fall 18.1% to A$0.655, on track for their biggest-ever intraday drop** Wound healing products maker fell as much as 19.1% earlier in the day, hitting lowest level since Dec. 18** Co cuts FY25 normalised EBITDA profit guidance to a range between NZ$2 mln  and NZ$4 mln, from earlier guidance of NZ$2 mln to NZ$6 mln ** Cuts FY25 total revenue guidance to between NZ$81 mln and NZ$84 mln from earlier guidance of NZ$80 mln to NZ$87 mln** About 901,488 shares change hand, compared to 30-day average trading volume of 318,195 shares ** Stock down around 15% this year, including the day's moves     ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nL3N3OP02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2507521507","title":"Aroa Biosurgery Sees FY Normalised Ebitda Profit of Nz$2-4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2507521507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507521507?lang=en_us&edition=fundamental","pubTime":"2025-01-29 05:55","pubTimestamp":1738101312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO18D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2507252150","title":"Aroa Biosurgery Ltd -  Full-Year FY25 Guidance Expected to Be Nz$81-84 Mln Total Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2507252150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507252150?lang=en_us&edition=fundamental","pubTime":"2025-01-29 05:55","pubTimestamp":1738101312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO18D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2504710919","title":"New study highlights effectiveness and cost benefits of Myriad™ in lower limb salvage surgeries.","url":"https://stock-news.laohu8.com/highlight/detail?id=2504710919","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504710919?lang=en_us&edition=fundamental","pubTime":"2025-01-17 09:54","pubTimestamp":1737078840,"startTime":"0","endTime":"0","summary":"AUCKLAND, New Zealand, Jan. 16, 2025 /PRNewswire/ -- New Zealand headquartered soft tissue regeneration companyAroa Biosurgery recently announced the publication of further strong clinical evidence reinforcing both efficacy and cost benefits of its AROA ECM technology when used in high-risk limb salvage surgery.Conducted between May 2022 and April 2023, the single site prospective clinical study included a total of130 complex lower limb defects from 120 patients.A staggering 95% of patients enrolled in the study had at least one risk factor for lower limb amputation, and 55% had 3 or more predictive risk factors for amputation.The study's lead Investigator Dr. John Lawlor is an experienced Foot and Ankle Surgeon based in Florida. \"I've been using AROA's Myriad products for several years now and have seen the difference Myriad can make in my own patient population. It's very encouraging to see this large study published, quantifying the significant positive impact to patients, as well t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/study-highlights-effectiveness-cost-benefits-015400626.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/study-highlights-effectiveness-cost-benefits-015400626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2503046586","title":"Insider Returns Down To NZ$223k As Aroa Biosurgery's Stock Dips 10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503046586","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503046586?lang=en_us&edition=fundamental","pubTime":"2025-01-16 04:56","pubTimestamp":1736974596,"startTime":"0","endTime":"0","summary":"Insiders who purchased Aroa Biosurgery Limited ( ASX:ARX ) shares in the past 12 months are unlikely to be deeply...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/insider-returns-down-to-nz223k-as-aroa-biosurgerys-stock-dip","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2503681875","title":"Companies Like Aroa Biosurgery (ASX:ARX) Can Afford To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2503681875","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503681875?lang=en_us&edition=fundamental","pubTime":"2025-01-15 04:02","pubTimestamp":1736884975,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.So should Aroa Biosurgery  shareholders be worried about its cash burn?In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/companies-aroa-biosurgery-asx-arx-200255207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2493135277","title":"Aroa Biosurgery Says Real-World Study Backs Efficacy of Regenerative Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2493135277","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493135277?lang=en_us&edition=fundamental","pubTime":"2024-12-23 09:50","pubTimestamp":1734918617,"startTime":"0","endTime":"0","summary":"Aroa Biosurgery  said a real-world study showed the efficacy of its Myriad product designed for limb reconstruction procedures, according to a Monday filing with the Australian bourse.The study, conducted in patients with high risks of complications and amputations, showed that the Myriad Matrix and Myriad Morcells regenerative products were able to achieve full coverage with no infections and complications, the filing said.The study covered 120 patients with 130 lower limb defects, the filing said. Across all participants, 95% had at least one risk factor for amputation, and 55% had three or more risk factors.Results were published in the peer-reviewed journal Plastic and Reconstructive Surgery - Global Open.The company's shares gained close to 2% in recent Monday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2492997217","title":"Insiders own 25% of Aroa Biosurgery Limited (ASX:ARX) shares but individual investors control 51% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2492997217","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492997217?lang=en_us&edition=fundamental","pubTime":"2024-12-18 04:03","pubTimestamp":1734465797,"startTime":"0","endTime":"0","summary":"The considerable ownership by individual investors in Aroa Biosurgery indicates that they collectively have a greater say in management and business strategy. To get a sense of who is truly in control of Aroa Biosurgery Limited , it is important to understand the ownership structure of the business. We can see that individual investors own the lion's share in the company with 51% ownership. That is, the group stands to benefit the most if the stock rises .And individual insiders on the other hand have a 25% ownership in the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies.Let's take a closer look to see what the different types of shareholders can tell us about Aroa Biosurgery.ASX:ARX Earnings and Revenue Growth December 17th 2024. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the ve","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insiders-own-25-aroa-biosurgery-200317009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2489238021","title":"Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489238021","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489238021?lang=en_us&edition=fundamental","pubTime":"2024-12-05 04:01","pubTimestamp":1733342463,"startTime":"0","endTime":"0","summary":"Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-limited-asxarx-held-back-by-insufficient-gro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2486359290","title":"The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2486359290","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486359290?lang=en_us&edition=fundamental","pubTime":"2024-11-28 07:31","pubTimestamp":1732750305,"startTime":"0","endTime":"0","summary":"It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/the-aroa-biosurgery-limited-asxarx-interim-results-are-out-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2486856028","title":"ASX Penny Stocks To Watch In November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486856028","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486856028?lang=en_us&edition=fundamental","pubTime":"2024-11-27 07:07","pubTimestamp":1732662458,"startTime":"0","endTime":"0","summary":"The Australian market is showing resilience, with the ASX 200 expected to gain despite global economic uncertainties, such as newly proposed tariffs and geopolitical tensions. In this context, investors might find interest in penny stocks—typically smaller or newer companies that offer a blend of affordability and growth potential. While the term \"penny stocks\" may seem outdated, these investments can still present compelling opportunities when they exhibit strong financials and solid fundamentals.Overview: Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology in the United States and internationally, with a market cap of A$231.08 million.Impact Minerals, with a market cap of A$39.77 million, remains pre-revenue, reporting minimal sales of A$0.12 million and a net loss","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CgF_bHzIPDCsG3KwCCLvew--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2bc7e9c938f83604e86f7ffd61b40d2a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CgF_bHzIPDCsG3KwCCLvew--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2bc7e9c938f83604e86f7ffd61b40d2a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-penny-stocks-watch-november-230738990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVX.AU","IPT.AU","BK4157","NVX","ARX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-05-31","symbol":"ARX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1748649600000,"name":null,"time":"","dateTimestamp":1748613600000,"actualEps":null},{"date":"2025-04-29","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1745884800000,"name":null,"time":"Pre-Market","dateTimestamp":1745848800000,"actualEps":null},{"date":"2025-01-28","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1738018800000,"name":null,"time":"Pre-Market","dateTimestamp":1737982800000,"actualEps":null},{"date":"2024-10-21","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1729465200000,"name":null,"time":"Pre-Market","dateTimestamp":1729429200000,"actualEps":null},{"date":"2024-05-21","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1716249600000,"name":null,"time":"Pre-Market","dateTimestamp":1716213600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARX.AU\",market:\"AU\",,,undefined,":[]}}